On Demand: Outsmarting the Heart: A Novel Device Therapy Targeting the Neurohormonal Pathways in Heart Failure Patients-Webinar Recording

Video Transcription

Video Summary

The webinar "Outsmarting the Heart" focused on a novel device therapy targeting neurohormonal pathways in heart failure patients. Led by Dr. Patrick McCann, along with James Kreiner and Bonnie Hankey, it highlighted significant issues with heart failure management, especially the challenges with optimizing guideline-directed medical therapy (GDMT). Current GDMT is often underutilized, leading to increased hospitalizations and persistent symptoms, which create opportunities for device therapies like baroreceptor activation therapy (Barostim).<br /><br />Barostim, implanted similarly to a pacemaker, targets baroreceptor signaling to balance sympathetic and parasympathetic activity, improving exercise capacity, quality of life, and reducing hospitalizations. The device benefits are maximized in stage C heart failure patients not fully responding to GDMT. The webinar stressed the importance of early intervention with Barostim for better outcomes. Bonnie Hankey discussed coding and reimbursement details, while Jim Kreiner shared administrative insights on establishing and maintaining a successful device therapy program. Overall, the webinar underscored Barostim's role as a valuable tool in the heart failure treatment arsenal, complementing traditional therapies rather than replacing them.

Keywords

heart failure

device therapy

Barostim

neurohormonal pathways

GDMT

hospitalizations

Baroreceptor activation

exercise capacity

early intervention